COMBI Stock Overview
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden.
Price History & Performance
|Historical stock prices|
|Current Share Price||kr7.95|
|52 Week High||kr20.05|
|52 Week Low||kr6.12|
|1 Month Change||-6.47%|
|3 Month Change||-1.49%|
|1 Year Change||15.89%|
|3 Year Change||-64.67%|
|5 Year Change||-84.41%|
|Change since IPO||-95.56%|
Recent News & Updates
|COMBI||SE Biotechs||SE Market|
Return vs Industry: COMBI exceeded the Swedish Biotechs industry which returned -38.8% over the past year.
Return vs Market: COMBI exceeded the Swedish Market which returned -27.2% over the past year.
|COMBI Average Weekly Movement||8.2%|
|Biotechs Industry Average Movement||8.2%|
|Market Average Movement||6.9%|
|10% most volatile stocks in SE Market||11.7%|
|10% least volatile stocks in SE Market||4.3%|
Stable Share Price: COMBI is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: COMBI's weekly volatility has decreased from 25% to 8% over the past year.
About the Company
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies.
CombiGene Fundamentals Summary
|COMBI fundamental statistics|
Is COMBI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|COMBI income statement (TTM)|
|Cost of Revenue||kr49.06m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 11, 2022
|Earnings per share (EPS)||2.48|
|Net Profit Margin||42.92%|
How did COMBI perform over the long term?See historical performance and comparison
Is COMBI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for COMBI?
Other financial metrics that can be useful for relative valuation.
|What is COMBI's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does COMBI's PE Ratio compare to its peers?
|COMBI PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
BIOG B BioGaia
Price-To-Earnings vs Peers: COMBI is good value based on its Price-To-Earnings Ratio (3.2x) compared to the peer average (37x).
Price to Earnings Ratio vs Industry
How does COMBI's PE Ratio compare vs other companies in the European Biotechs Industry?
Price-To-Earnings vs Industry: COMBI is good value based on its Price-To-Earnings Ratio (3.2x) compared to the European Biotechs industry average (34.5x)
Price to Earnings Ratio vs Fair Ratio
What is COMBI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||3.2x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate COMBI's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of COMBI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: COMBI (SEK7.95) is trading below our estimate of fair value (SEK315.79)
Significantly Below Fair Value: COMBI is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is CombiGene forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CombiGene has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
How has CombiGene performed over the past 5 years?
Past Performance Score4/6
Past Performance Score 4/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: COMBI has high quality earnings.
Growing Profit Margin: COMBI became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: COMBI has become profitable over the past 5 years, growing earnings by 10.9% per year.
Accelerating Growth: COMBI has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: COMBI has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-15.8%).
Return on Equity
High ROE: COMBI's Return on Equity (30.6%) is considered high.
Discover strong past performing companies
How is CombiGene's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: COMBI's short term assets (SEK145.2M) exceed its short term liabilities (SEK5.4M).
Long Term Liabilities: COMBI's short term assets (SEK145.2M) exceed its long term liabilities (SEK1,000.0).
Debt to Equity History and Analysis
Debt Level: COMBI is debt free.
Reducing Debt: COMBI had no debt 5 years ago.
Debt Coverage: COMBI has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: COMBI has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is CombiGene current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate COMBI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate COMBI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if COMBI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if COMBI's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as COMBI has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jan Nilsson (73 yo)
Mr. Jan Nilsson serves as Director at Aptahem AB (publ) since 2022. He has been Chief Executive Officer at CombiGene AB (publ) since October 1, 2016 and also served as it's Director since 2020 until May 20...
CEO Compensation Analysis
Compensation vs Market: Jan's total compensation ($USD210.86K) is about average for companies of similar size in the Swedish market ($USD222.72K).
Compensation vs Earnings: Jan's compensation has been consistent with company performance over the past year.
Experienced Management: COMBI's management team is considered experienced (4.7 years average tenure).
Experienced Board: COMBI's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
CombiGene AB (publ)'s employee growth, exchange listings and data sources
- Name: CombiGene AB (publ)
- Ticker: COMBI
- Exchange: OM
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: kr157.420m
- Shares outstanding: 19.80m
- Website: https://www.combigene.com
Number of Employees
- CombiGene AB (publ)
- Agavagen 52A
- Stockholm County
- 181 55
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|COMBI||OM (OMX Nordic Exchange Stockholm)||Yes||Share Capital||SE||SEK||May 2015|
|COJ0||DB (Deutsche Boerse AG)||Yes||Share Capital||DE||EUR||May 2015|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/22 00:00|
|End of Day Share Price||2022/09/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.